The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients

Figures & data

Table 1 Patient and Tumor Features

	EC-D (Total:109)				EC-P (Total346)
	ypT0/isN0	No ypT0/isN0	ypT0N0	No ypT0N0	ypT0/isN0	No ypT0/isN0	ypT0N0	No ypT0N0
Age of diagnosis
≤45	1(0.92%)	27(24.77%)	1(0.92%)	27(24.77%)	22(6.36%)	99(28.61%)	12(3.47%)	109(31.50%)
45–60	7(6.42%)	53(48.62%)	4(3.67%)	56(51.37%)	34(9.83%)	142(41.04%)	20(5.78%)	156(45.09%)
>60	3(2.75%)	18(16.52)	1(0.92%)	20(18.35%)	11(3.18%)	38(10.98%)	11(3.18%)	38(10.98%)
Menstrual status
Premenopausal	4(3.66%)	47(43.12%)	2(1.84%)	49(44.95%)	38(10.98%)	150(43.35%)	18(5.20%)	170(49.13%)
Peri-menopause	1(0.92%)	3(2.75%)	1(0.92%)	3(2.75%)	0(0)	8(2.31%)	0(0)	8(2.31%)
Postmenopausal	6(5.51%)	47(43.12%)	3(2.75%)	50(45.87%)	29(8.38%)	115(33.24%)	25(7.23%)	119(34.39%)
Unknown	0(0)	1(0.92%)	0(0)	1(0.92%)	0(0)	6(1.74%)	0(0)	6(1.74%)
Molecular type
Luminal A	0(0)	1(0.92%)	0(0)	1(0.92%)	0(0)	13(3.76%)	0(0)	13(3.76%)
Luminal B	3(2.75%)	66(60.55%)	2(1.83%)	67(61.47%)	23(6.65%)	156(45.09%)	9(2.60%)	170(49.13%)
Her2 overexpression	6(5.50%)	22(20.18%)	3(2.75%)	25(22.94%)	25(7.22%)	47(13.58%)	17(4.91%)	55(15.90%)
TNBC	2(1.84%)	7(6.42%)	1(0.92%)	8(7.34%)	19(5.49%)	55(15.90%)	17(4.91%)	57(16.47%)
Unknown	0(0)	2(1.84%)	0(0)	2(1.83%)	0(0)	8(2.31%)	0(0)	8(2.32%)
ER status
Positive	3(2.75%)	68(62.39%)	2(1.84%)	69(63.30%)	23(6.65%)	167(48.26%)	9(2.60%)	181(52.31%)
Negative	8(7.34%)	28(25.69%)	4(3.66%)	32(29.36%)	44(12.72%)	105(30.35%)	34(9.83%)	115(33.24%)
Unknown	0(0)	2(1.83%)	0(0)	2(1.84%)	0(0)	7(2.02%)	0(0)	7(2.02%)
PR status
Positive	2(1.84%)	45(41.28%)	2(1.84%)	45(41.28%)	13(3.76%)	140(40.46%)	4(1.16%)	149(43.06%)
Negative	9(8.26%)	50(45.87%)	4(3.67%)	55(50.46%)	54(15.61%)	131(37.86%)	39(11.27%)	146(42.20%)
Unknown	0(0)	3(2.75%)	0(0)	3(2.75%)	0(0)	8(2.31%)	0(0)	8(2.31%)
Her-2 status
Positive	9(8.25%)	38(34.86%)	5(4.58%)	42(38.53%)	39(11.27%)	92(26.59%)	21(6.07%)	110(31.79%)
Negative	2(1.84%)	58(53.21%)	1(0.92%)	59(54.13%)	28(8.09%)	178(51.45%)	22(6.36%)	184(53.18%)
Unknown	0(0)	2(1.84%)	0(0)	2(1.84%)	0(0)	9(2.60%)	0(0)	9(2.60%)
Ki-67 index
≤ 14%	0(0)	3(2.75%)	0(0)	3(2.75%)	1(0.29%)	28(8.09%)	0(0)	29(8.38%)
> 14%	11(10.09%)	93(85.32%)	6(5.50%)	98(89.91%)	66(19.08%)	243(70.23%)	43(12.43%)	266(76.88%)
Unknown	0(0)	2(1.84%)	0(0)	2(1.84%)	0(0)	8(2.31%)	0(0)	8(2.31%)

Table 2 The Analysis of ypT_0/isN₀

	ypT0/isN0	No ypT0/isN0		p	OR (95% CI)	p
Chemotherapy			5.017	0.025
EC-D	11(2.41%)	98(21.54%)			1.797(0.882, 3.660)	0.106
EC-P	67(14.73%)	279(61.32%)
Age of diagnosis			0.717	0.699
≤45	23(5.05%)	126(27.69%)
45–60	41(9.01%)	195(42.86%)
>60	14(3.08%)	56(12.31%)
Menstrual status			2.189	0.534
Premenopausal	42(9.23%)	197(43.30%)
Peri-menopause	1(0.22%)	11(2.42%)
Postmenopausal	35(7.69%)	162(35.60%)
Unknown	0(0)	7(1.54%)
Molecular type			30.116	<0.001
Luminal A	0(0)	14(3.08%)			9.495(2.492, 36.176)	0.001
Luminal B	26(5.71%)	222(48.79%)
Her2 overexpression	31(6.81%)	69(15.16%)
TNBC	21(4.62%)	62(13.63%)
Unknown	0(0)	10(2.20%)
ER status			26.998	<0.001
Positive	26(5.71%)	235(51.65%)			0.085(0.013, 0.561)	0.01
Negative	52(11.43%)	133(29.23%)
Unknown	0(0)	9(1.98%)
PR status			28.301	<0.001
Positive	15(3.30%)	185(40.66%)			1.395(0.46, 4.23)	0.556
Negative	63(13.84%)	181(39.78%)
Unknown	0(0)	11(2.42%)
Her-2 status			20.81	<0.001
Positive	48(10.55%)	130(28.57%)			0.055(0.017, 0.183)	<0.001
Negative	30(6.59%)	236(51.87%)
Unknown	0(0)	11(2.42%)
Ki-67 index			7.151	0.028
≤ 14%	1(0.22%)	31(6.81%)			0.444(0.089, 2.219)	0.323
> 14%	77(16.92%)	336(73.85%)
Unknown	0(0)	10(2.20%)

Table 3 The Analysis of ypT₀N₀

	ypT0N0	No ypT0N0		p	OR (95% CI)	p
Chemotherapy			4.134	0.042
EC-D	6(1.32%)	103(22.64%)			3.379(1.373, 8.314)	0.008
EC-P	43(9.45%)	303(66.59%)
Age of diagnosis			3.696	0.158
≤45	13(2.85%)	136(29.89%)
45–60	24(5.28%)	212(46.59%)
>60	12(2.64%)	58(12.75%)
Menstrual status			4.784	0.188
Premenopausal	20(4.40%)	219(48.13%)
Peri-menopause	1(0.22%)	11(2.42%)
Postmenopausal	28(6.15%)	169(37.14%)
Unknown	0(0)	7(1.54%)
Molecular type			32.412	<0.001
Luminal A	0(0)	14(3.08%)			21.3(3.651, 124.264)	0.001
Luminal B	11(2.42%)	237(52.09%)
Her2 overexpression	20(4.39%)	80(17.58%)
TNBC	18(3.95%)	65(14.29%)
Unknown	0(0)	10(2.20%)
ER status			31.137	<0.001
Positive	11(2.42%)	250(54.94%)			0.104(0.011, 0.991)	0.049
Negative	38(8.35%)	147(32.31%)
Unknown	0(0)	9(1.98%)
PR status			25.818	<0.001
Positive	6(1.32%)	194(42.64%)			0.262(0.059, 1.154)	0.077
Negative	43(9.45%)	201(44.17%)
Unknown	0(0)	11(2.42%)
Her-2 status			5.303	0.071
Positive	26(5.71%)	152(33.41%)
Negative	23(5.05%)	243(53.41%)
Unknown	0(0)	11(2.42%)
Ki-67 index			5.584	0.061
≤ 14%	0(0)	32(7.03%)
> 14%	49(10.77%)	364(80.00%)
Unknown	0(0)	10(2.20%)

Table 4 The ypT_0/isN₀ Rate Analysis of EC-D

EC-D	ypT0/isN0	No ypT0/isN0		p	OR (95% CI)	p’
Age of diagnosis			1.883	0.39
≤45	1	27
45–60	7	53
>60	3	18
Menstrual status			1.465	0.69
Premenopausal	4	47
Peri-menopause	1	3
Postmenopausal	6	47
Unknown	0	1
Molecular type			8.272	0.082
Luminal A	0	1
Luminal B	3	66
Her2 overexpression	6	22
TNBC	2	7
Unknown	0	2
ER status			8.756	0.013
Positive	3	68			—–	1
Negative	8	28
Unknown	0	2
PR status			3.834	0.147
Positive	2	45
Negative	9	50
Unknown	0	3
Her-2 status			7.494	0.024
Positive	9	38
Negative	2	58				0.997
Unknown	0	2
Ki-67 index			0.588	0.745
≤ 14%	0	3
> 14%	11	93
Unknown	0	2

Table 5 The ypT₀N₀ Rate Analysis of EC-D

EC-D	ypT0N0	No ypT0N0		p	OR (95% CI)	p’
Age of diagnosis			0.379	0.827
≤45	1	27
45–60	4	56
>60	1	20
Menstrual status			3.229	0.358
Premenopausal	2	49
Peri-menopause	1	3
Postmenopausal	3	50
Unknown	0	1
Molecular type			3.081	0.544
Luminal A	0	1
Luminal B	2	67
Her2 overexpression	3	25
TNBC	1	8
Unknown	0	2
ER status			3.278	0.194
Positive	2	69
Negative	4	32
Unknown	0	2
PR status			0.5	0.779
Positive	2	45
Negative	4	55
Unknown	0	3
Her-2 status			4.197	0.123
Positive	5	42
Negative	1	59
Unknown	0	2
Ki-67 index			0.305	0.858
≤ 14%	0	3
> 14%	6	98
Unknown	0	2

Table 6 The ypT_0/isN₀ Rate Analysis of EC-P

EC-P	ypT0/isN0	No ypT0/isN0		p	OR (95% CI)	p’
Age of diagnosis			0.407	0.816
≤45	22	99
45–60	34	142
>60	11	38
Menstrual status			3.504	0.32
Premenopausal	38	150
Peri-menopause	0	8
Postmenopausal	29	115
Unknown	0	6
Molecular type			22.673	<0.001
Luminal A	0	13			4.214(1.105, 16.065)	0.035
Luminal B	23	156
Her2 overexpression	25	47
TNBC	19	55
Unknown	0	8
ER status			17.955	<0.001
Positive	23	167			0.253(0.036, 1.796)	0.17
Negative	44	105
Unknown	0	7
PR status			24.93	<0.001
Positive	13	140			2.439(0.619, 9.608)	0.203
Negative	54	131
Unknown	0	8
Her-2 status			15.643	<0.001
Positive	39	92
Negative	28	178			0.126(0.038, 0.414)	0.001
Unknown	0	9
Ki-67 index			7.414	0.025
≤ 14%	1	28			0.397(0.088, 1.789)	0.229
> 14%	66	243
Unknown	0	8

Table 7 The ypT₀N₀ Rate Analysis of EC-P

EC-P	ypT0N0	No ypT0N0		p	OR (95% CI)	p’
Age of diagnosis			5.405	0.067
≤45	12	109
45–60	20	156
>60	11	38
Menstrual status			6.613	0.085
Premenopausal	18	170
Peri-menopause	0	8
Postmenopausal	25	119
Unknown	0	6
Molecular type			27.821	<0.001
Luminal A	0	13			11.571(1.838, 72.83)	0.009
Luminal B	9	170
Her2 overexpression	17	55
TNBC	17	57
Unknown	0	8
ER status			26.102	<0.001
Positive	9	181			0.22(0.021, 2.329)	0.208
Negative	34	115
Unknown	0	7
PR status			27.402	<0.001
Positive	4	149			0.463(0.088, 2.429)	0.362
Negative	39	146
Unknown	0	8
Her-2 status			3.418	0.181
Positive	21	110
Negative	22	184
Unknown	0	9
Ki-67 index			5.88	0.053
≤ 14%	0	29
> 14%	43	266
Unknown	0	8

Table 8 Blood and Kidney Marker Analysis

	EC-D (n=87)	EC-P (n=230)	z	P
HGB	−0.06(−0.12, −0.01)	−0.1 (−0.15, −0.05)	3.07	0.0021
PLA	−0.01(−0.17,0.11)	−0.03(−0.17,0.13)	0.295	0.7683
UREA	0.04(−0.18,0.27)	0.00(−0.22,0.25)	0.843	0.399
Cr	0.00 (−0.07,0.07)	−0.06(−0.14,0.03)	3.527	0.0004

Table 9 Trastuzumab Analysis

	Total	ypT0/isN0	ypT0N0
Trastuzumab	126	40(31.70%)	23(18.25%)
No trastuzumab	52	9(17.31%)	4(7.69%)
p		<0.05	<0.05